Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $338,000.

  • Xeris Biopharma Holdings' Depreciation & Amortization (CF) rose 10.10% to $338,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 1.41%. This contributed to the annual value of $1.2 million for FY2024, which is 18.20% down from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Depreciation & Amortization (CF) stood at $338,000, which was up 4.00% from $325,000 recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Depreciation & Amortization (CF) high stood at $391,000 for Q3 2023, and its period low was $281,000 during Q2 2024.
  • Over the past 3 years, Xeris Biopharma Holdings' median Depreciation & Amortization (CF) value was $326,000 (recorded in 2024), while the average stood at $336,818.
  • In the last 5 years, Xeris Biopharma Holdings' Depreciation & Amortization (CF) decreased by 27.20% in 2024 and then grew by 15.66% in 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Depreciation & Amortization (CF) (Quarterly) stood at $349,000 in 2021, then grew by 5.16% to $367,000 in 2022, then declined by 2.18% to $359,000 in 2023, then decreased by 12.81% to $313,000 in 2024, then grew by 10.10% to $338,000 in 2025.
  • Its Depreciation & Amortization (CF) was $338,000 in Q3 2025, compared to $325,000 in Q2 2025 and $315,000 in Q1 2025.